Why are biotech stocks in the dumps? Is the latest in cancer care overhyped? And what does “folie à deux” mean?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dig into what was an abysmal month for biotech on Wall Street and pick apart whether better days might be ahead. Then, Kaiser Health News senior correspondent Liz Szabo joins us to talk about the financial toxicity that cancer patients face for pricey tests and targeted treatments. And STAT deputy multimedia and creative director Alissa Ambrose talks about her experience with postpartum depression, an underdiscussed condition that affects about 15 percent of mothers who have recently given birth. Finally, we touch on pharmaceutical tourism to Mexico, the latest biopharma prison sentencing, and some questionable calls from Celgene CEOs new and old.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy